| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |